Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients
Jennifer Foglietta, Alessandro Inno, Francesca de Iuliis, Valentina Sini, Simona Duranti, Monica Turazza, Luigi Tarantini, Stefania Gori
Clin Breast Cancer. 2017 Feb;17(1):11-17
CARDIONCOLOGY.ORG ABSTRACT:
Aromatase inhibitors represent an effective endocrine treatment for patients with hormone receptor-positive breast cancer, in early stage and in metastatic disease.
However, such treatment may also potentially reduce the protective effect of estrogens on the cardiovascular system, leading to hyperlipidemia, hypercholesterolemia, and hypertension.
This article reviews the literature on cardiotoxicity of aromatase inhibitors to compare them with tamoxifen and provide practical advice to improve the cardiovascular safety profile of these drugs.
© All Rights Reserved